Kimmtrak Data Challenge Long-Held Assumptions About Immunotherapy in Uveal Melanoma

Presented at the 2026 American Association for Cancer Research Annual Meeting, the five-year follow-up data from the Phase 3 Kimmtraktrial showed sustained overall survival benefit with Kimmtrak(tebentafusp-tebn), the first approved T-cell receptor (TCR) therapy for HLA-A*02:01-positive adults with metastatic uveal melanoma.

What Do the Results Suggest About the Future of TCR Therapies in Solid Tumors?

In an interview with BioPharm International, Dr. Alexander Shoushtari, melanoma oncologist and cellular therapist at Memorial Sloan Kettering Cancer Center, said the data reinforce the value of precision immune-targeting strategies in solid tumors that historically have been viewed as poor candidates for immunotherapy.

For years, uveal melanoma was often cited as an example of a cancer that failed to respond meaningfully to immune checkpoint inhibitors. According to Shoushtari, the Kimmtrak experience demonstrates that successful immunotherapy depends on selecting the right target and mechanism rather than broadly categorizing tumors as immunologically “hot” or “cold.”

“I think what this trial has really shown is that you have to get more precise as a scientist, and you have to be more aware as a physician that different tools now exist to manipulate the body's immune system to fight cancer,” Shoushtari said.

The trial also demonstrated consistent benefit across multiple patient subgroups, including those with characteristics traditionally associated with poorer outcomes. Although subgroup analyses were not powered to establish definitive differences, Shoushtari said the consistent trend favoring tebentafusp strengthens confidence in recommending the therapy across a broad patient population.

The findings may have implications beyond uveal melanoma. As researchers continue developing TCR-based therapies and other targeted immune approaches, the study offers evidence that carefully designed immunotherapies can achieve meaningful outcomes even in cancers previously considered unlikely to benefit from immune modulation.

For Shoushtari, the broader lesson is clear: “This is really proving that nuance is important.”

About the speaker

Alexander Shoushtari, MD, medical oncologist and cellular therapist, Memorial Sloan Kettering Cancer Center

Dr. Alexander N. Shoushtari, MD, is a board-certified medical oncologist and cellular therapist at Memorial Sloan Kettering Cancer Center (MSK), where he leads the institution’s largest melanoma practice. With more than 15 years of clinical experience, he specializes in rare and difficult-to-treat melanomas, including uveal, mucosal, and acral melanoma, as well as advanced immunotherapy and tumor-infiltrating lymphocyte (TIL) therapies. An associate attending physician and active clinical researcher, Dr. Shoushtari has authored more than 150 peer-reviewed publications and has served as principal investigator on multiple clinical trials evaluating novel immuno-oncology therapies, including tebentafusp and ONCOS-102. He earned his medical degree from Rush Medical College of Rush University Medical Center and is board-certified in Internal Medicine and Medical Oncology.